問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Study Statistics

5316Cases

20022027

Total

5316

  • I

    573

  • I/II

    251

  • II

    1225

  • II/III

    138

  • III

    2607

  • IV

    105

  • Others

    356

Principal Investigator

2769Doctors

Co-Principal Investigator

8934Doctors

Hospital

125Sites

List

5316Cases

2023-09-01 - 2028-02-29

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2026-08-01 - 2027-10-31

Phase III

Not yet recruiting
A phase 3, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of ALKS 2680 in adult patients with type 1 narcolepsy.

  • Condition/Disease

    narcolepsy

  • Test Drug

    ALKS 2680 2 mg tablet ALKS 2680 4 mg tablet ALKS 2680 6 mg tablet ALKS 2680 Placebo Tablet Orange

Participate Sites
5Sites

Not yet recruiting1Sites

2023-09-01 - 2027-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-09-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-09-01 - 2028-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB